Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has reported that the US District Court for the District of Delaware has found all four patents in a suit involving Johnson & Johnson, to be invalid. The Court ruled that a trial on the four patents, which was scheduled to begin on February 9, will not proceed.
Subscribe to our email newsletter
Reportedly, as part of a 2007 suit, Johnson & Johnson has alleged that Boston Scientific’s Promus Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings (drug and polymer) for drug-eluting stents.
Ray Elliott, president and CEO of Boston Scientific, said: “We are pleased with the Court’s finding that all four Johnson & Johnson patents are invalid. Boston Scientific will continue to vigorously defend against any charges of infringement. We continue to attempt to resolve remaining outstanding matters with Johnson & Johnson.”
Boston Scientific is a manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.